p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancer

G. Ferrandina, A. Fagotti, M. G. Salerno, P. G. Natali, M. Mottolese, F. Maneschi, A. De Pasqua, P. Benedetti-Panici, S. Mancuso, G. Scambia

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

The aim of this study was to assess the association of p53 status with primary cytoreduction, response to chemotherapy and outcome in stage III-IV primary ovarian cancer patients. Immunohistochemical analysis of p53 was performed on formalin-fixed, paraffin-embedded specimens from 168 primary ovarian carcinomas by using the DO-7 monoclonal antibody. p53 nuclear positivity was found in 84 out of 162 (52%) malignant tumours. A higher percentage of p53 nuclear positivity was observed in patients with advanced stage of disease than in stage I-II (57% vs 23% respectively; P = 0.0022) and in poorly differentiated versus well/moderately differentiated tumours (59% vs 32% respectively; P = 0.0038). The multivariate analysis aimed to investigate the association of FIGO stage, grade and p53 status with primary cytoreduction in 136 stage III-IV patients showed that stage IV disease may influence the possibility to perform primary cytoreduction in ovarian cancer patients. p53-positivity also maintained a trend to be associated with poor chance of cytoreduction. In patients who underwent pathologic assessment of response, cases who did not respond to chemotherapy were much more frequently p53-positive than p53-negative (86% vs 14% respectively; P = 0.012). Moreover, patients with stage III disease and <2-cm residual tumour were more likely to respond to treatment. In multivariate analysis, FIGO stage and p53 expression were independently correlated with pathologic response to chemotherapy. Time to progression and survival rates were shown not to be different in p53-positive versus p53-negative patients.

Original languageEnglish
Pages (from-to)733-740
Number of pages8
JournalBritish Journal of Cancer
Volume81
Issue number4
DOIs
Publication statusPublished - 1999

Fingerprint

Ovarian Neoplasms
Drug Therapy
Multivariate Analysis
Residual Neoplasm
Paraffin
Formaldehyde
Neoplasms
Survival Rate
Carcinoma

Keywords

  • Cytoreduction
  • Ovarian cancer
  • p53
  • Response to chemotherapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Ferrandina, G., Fagotti, A., Salerno, M. G., Natali, P. G., Mottolese, M., Maneschi, F., ... Scambia, G. (1999). p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancer. British Journal of Cancer, 81(4), 733-740. https://doi.org/10.1038/sj.bjc.6690756

p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancer. / Ferrandina, G.; Fagotti, A.; Salerno, M. G.; Natali, P. G.; Mottolese, M.; Maneschi, F.; De Pasqua, A.; Benedetti-Panici, P.; Mancuso, S.; Scambia, G.

In: British Journal of Cancer, Vol. 81, No. 4, 1999, p. 733-740.

Research output: Contribution to journalArticle

Ferrandina, G, Fagotti, A, Salerno, MG, Natali, PG, Mottolese, M, Maneschi, F, De Pasqua, A, Benedetti-Panici, P, Mancuso, S & Scambia, G 1999, 'p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancer', British Journal of Cancer, vol. 81, no. 4, pp. 733-740. https://doi.org/10.1038/sj.bjc.6690756
Ferrandina, G. ; Fagotti, A. ; Salerno, M. G. ; Natali, P. G. ; Mottolese, M. ; Maneschi, F. ; De Pasqua, A. ; Benedetti-Panici, P. ; Mancuso, S. ; Scambia, G. / p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancer. In: British Journal of Cancer. 1999 ; Vol. 81, No. 4. pp. 733-740.
@article{4a30d9b7d9e2459cbb837612f3e19297,
title = "p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancer",
abstract = "The aim of this study was to assess the association of p53 status with primary cytoreduction, response to chemotherapy and outcome in stage III-IV primary ovarian cancer patients. Immunohistochemical analysis of p53 was performed on formalin-fixed, paraffin-embedded specimens from 168 primary ovarian carcinomas by using the DO-7 monoclonal antibody. p53 nuclear positivity was found in 84 out of 162 (52{\%}) malignant tumours. A higher percentage of p53 nuclear positivity was observed in patients with advanced stage of disease than in stage I-II (57{\%} vs 23{\%} respectively; P = 0.0022) and in poorly differentiated versus well/moderately differentiated tumours (59{\%} vs 32{\%} respectively; P = 0.0038). The multivariate analysis aimed to investigate the association of FIGO stage, grade and p53 status with primary cytoreduction in 136 stage III-IV patients showed that stage IV disease may influence the possibility to perform primary cytoreduction in ovarian cancer patients. p53-positivity also maintained a trend to be associated with poor chance of cytoreduction. In patients who underwent pathologic assessment of response, cases who did not respond to chemotherapy were much more frequently p53-positive than p53-negative (86{\%} vs 14{\%} respectively; P = 0.012). Moreover, patients with stage III disease and <2-cm residual tumour were more likely to respond to treatment. In multivariate analysis, FIGO stage and p53 expression were independently correlated with pathologic response to chemotherapy. Time to progression and survival rates were shown not to be different in p53-positive versus p53-negative patients.",
keywords = "Cytoreduction, Ovarian cancer, p53, Response to chemotherapy",
author = "G. Ferrandina and A. Fagotti and Salerno, {M. G.} and Natali, {P. G.} and M. Mottolese and F. Maneschi and {De Pasqua}, A. and P. Benedetti-Panici and S. Mancuso and G. Scambia",
year = "1999",
doi = "10.1038/sj.bjc.6690756",
language = "English",
volume = "81",
pages = "733--740",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - p53 overexpression is associated with cytoreduction and response to chemotherapy in ovarian cancer

AU - Ferrandina, G.

AU - Fagotti, A.

AU - Salerno, M. G.

AU - Natali, P. G.

AU - Mottolese, M.

AU - Maneschi, F.

AU - De Pasqua, A.

AU - Benedetti-Panici, P.

AU - Mancuso, S.

AU - Scambia, G.

PY - 1999

Y1 - 1999

N2 - The aim of this study was to assess the association of p53 status with primary cytoreduction, response to chemotherapy and outcome in stage III-IV primary ovarian cancer patients. Immunohistochemical analysis of p53 was performed on formalin-fixed, paraffin-embedded specimens from 168 primary ovarian carcinomas by using the DO-7 monoclonal antibody. p53 nuclear positivity was found in 84 out of 162 (52%) malignant tumours. A higher percentage of p53 nuclear positivity was observed in patients with advanced stage of disease than in stage I-II (57% vs 23% respectively; P = 0.0022) and in poorly differentiated versus well/moderately differentiated tumours (59% vs 32% respectively; P = 0.0038). The multivariate analysis aimed to investigate the association of FIGO stage, grade and p53 status with primary cytoreduction in 136 stage III-IV patients showed that stage IV disease may influence the possibility to perform primary cytoreduction in ovarian cancer patients. p53-positivity also maintained a trend to be associated with poor chance of cytoreduction. In patients who underwent pathologic assessment of response, cases who did not respond to chemotherapy were much more frequently p53-positive than p53-negative (86% vs 14% respectively; P = 0.012). Moreover, patients with stage III disease and <2-cm residual tumour were more likely to respond to treatment. In multivariate analysis, FIGO stage and p53 expression were independently correlated with pathologic response to chemotherapy. Time to progression and survival rates were shown not to be different in p53-positive versus p53-negative patients.

AB - The aim of this study was to assess the association of p53 status with primary cytoreduction, response to chemotherapy and outcome in stage III-IV primary ovarian cancer patients. Immunohistochemical analysis of p53 was performed on formalin-fixed, paraffin-embedded specimens from 168 primary ovarian carcinomas by using the DO-7 monoclonal antibody. p53 nuclear positivity was found in 84 out of 162 (52%) malignant tumours. A higher percentage of p53 nuclear positivity was observed in patients with advanced stage of disease than in stage I-II (57% vs 23% respectively; P = 0.0022) and in poorly differentiated versus well/moderately differentiated tumours (59% vs 32% respectively; P = 0.0038). The multivariate analysis aimed to investigate the association of FIGO stage, grade and p53 status with primary cytoreduction in 136 stage III-IV patients showed that stage IV disease may influence the possibility to perform primary cytoreduction in ovarian cancer patients. p53-positivity also maintained a trend to be associated with poor chance of cytoreduction. In patients who underwent pathologic assessment of response, cases who did not respond to chemotherapy were much more frequently p53-positive than p53-negative (86% vs 14% respectively; P = 0.012). Moreover, patients with stage III disease and <2-cm residual tumour were more likely to respond to treatment. In multivariate analysis, FIGO stage and p53 expression were independently correlated with pathologic response to chemotherapy. Time to progression and survival rates were shown not to be different in p53-positive versus p53-negative patients.

KW - Cytoreduction

KW - Ovarian cancer

KW - p53

KW - Response to chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=0032886486&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032886486&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6690756

DO - 10.1038/sj.bjc.6690756

M3 - Article

VL - 81

SP - 733

EP - 740

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 4

ER -